Neil Gallagher

Neil Gallagher M.D., Ph.D. brings substantial drug development experience in oncology. Most recently he was President of R&D at Syndax Pharmaceuticals, a company focused on developing first-in-class therapies in areas of significant unmet need. Prior to joining Syndax, he served as the Chief Medical Officer and Head of Development at AbbVie where he guided a number of development programs resulting in approval by the U.S. Food and Drug Administration (FDA). He has also held senior roles at Amgen, Novartis, AstraZeneca and Astex Therapeutics. He holds Non-Executive Board positions at Foghorn Therapeutics and Zymeworks and is a board advisor to Nouscom.